Quest Diagnostics Incorporated (DGX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $28.56B
Last updated: Nov 17, 2026 at 11:03 AM ET
Quest Diagnostics Incorporated (DGX) Financials: Revenue, Profit and Cash Flow
Quest Diagnostics reported revenue of $11.04B for the fiscal year ended Dec 31, 2025, up 11.8% from the year before. That year, net income was $1.05B with a net margin of 9.5%, operating cash flow was $1.89B and free cash flow was $1.36B. The quarter ended Sep 30, 2026 had revenue of $3.10B and net income of $326.00M.
Revenue and Margins
The operating margin was 14.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $7.21B, a compound annual rate of 4.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $11.04B | +11.8% | 33.2% | 14.1% | 9.5% |
| Dec 2024 | $9.87B | +6.7% | 32.9% | 13.6% | 9.3% |
| Dec 2023 | $9.25B | -6.4% | 33.0% | 13.6% | 9.8% |
| Dec 2022 | $9.88B | -8.4% | 34.7% | 14.4% | 10.3% |
| Dec 2021 | $10.79B | +14.3% | 39.0% | 22.1% | 19.3% |
| Dec 2020 | $9.44B | +22.1% | 38.5% | 20.9% | 15.9% |
| Dec 2019 | $7.73B | +2.6% | 34.8% | 15.9% | 11.7% |
| Dec 2018 | $7.53B | +1.7% | 34.6% | 14.6% | 10.5% |
| Dec 2017 | $7.40B | +2.6% | 36.2% | 15.7% | 11.1% |
| Dec 2016 | $7.21B | N/A | 36.0% | 17.7% | 9.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 14.0% from the year before. In the quarter ended Sep 2026, net income rose 25.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B |
| Cost of revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B |
| Gross profit | $3.67B | $3.24B | $3.05B | $3.43B | $4.21B | $3.63B | $2.69B | $2.60B | $2.68B | $2.60B |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B |
| Net income | $1.05B | $921.00M | $908.00M | $1.01B | $2.08B | $1.50B | $906.00M | $788.00M | $824.00M | $696.00M |
| EBITDA | $2.15B | $1.87B | $1.72B | $1.81B | $3.16B | $2.41B | $1.58B | $1.40B | $1.45B | $1.48B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.10B | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B |
| Gross profit | $1.04B | $1.03B | $942.00M | $910.00M | $949.00M | $943.00M | $863.00M | $858.00M | $811.00M | $804.00M | $771.00M | $736.00M |
| Operating income | $479.00M | $459.00M | $399.00M | $386.00M | $386.00M | $438.00M | $346.00M | $361.00M | $330.00M | $355.00M | $300.00M | $267.00M |
| Net income | $326.00M | $334.00M | $264.00M | $256.00M | $259.00M | $296.00M | $235.00M | $236.00M | $237.00M | $240.00M | $208.00M | $205.00M |
Balance Sheet
As of Dec 2025, total debt of $5.67B exceeded cash and equivalents by $5.25B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B |
| Current assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B |
| Cash and equivalents | $420.00M | $549.00M | $686.00M | $315.00M | $872.00M | $1.16B | $1.19B | $135.00M | $137.00M | $359.00M |
| Total liabilities | $8.94B | $9.26B | $7.60B | $6.83B | $7.05B | $7.13B | $7.08B | $5.66B | $5.47B | $5.36B |
| Short-term debt | $504.00M | $602.00M | $303.00M | $2.00M | $2.00M | $2.00M | $804.00M | $464.00M | $36.00M | $6.00M |
| Long-term debt | $5.17B | $5.62B | $4.41B | $3.98B | $4.01B | $4.01B | $3.97B | $3.43B | $3.75B | $3.73B |
| Shareholder equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $17.22B | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | $14.02B |
| Total liabilities | $9.19B | $9.04B | $8.93B | $8.94B | $8.82B | $8.62B | $8.75B | $9.26B | $9.17B | $7.15B | $7.41B | $7.60B |
| Cash and equivalents | $797.00M | $626.00M | $393.00M | $420.00M | $432.00M | $319.00M | $188.00M | $549.00M | $764.00M | $271.00M | $474.00M | $686.00M |
| Shareholder equity | $7.63B | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | $6.31B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 72.0% of operating cash flow. Dividends and share repurchases together came to 63.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B |
| Capital expenditures | $527.00M | $425.00M | $408.00M | $404.00M | $403.00M | $418.00M | $400.00M | $383.00M | $252.00M | $293.00M |
| Free cash flow | $1.36B | $909.00M | $864.00M | $1.31B | $1.83B | $1.59B | $843.00M | $817.00M | $923.00M | $823.00M |
| Dividends paid | $409.00M | $378.00M | $371.00M | $378.00M | $408.00M | $355.00M | $340.00M | $320.00M | $298.00M | $264.00M |
| Share repurchases | $450.00M | $151.00M | $275.00M | $1.41B | $2.20B | $325.00M | $353.00M | $322.00M | $465.00M | $590.00M |
| Investing cash flow | -$631.00M | -$2.55B | -$1.06B | -$543.00M | $21.00M | -$772.00M | -$411.00M | -$801.00M | -$830.00M | -$127.00M |
| Financing cash flow | -$1.39B | $1.08B | $160.00M | -$1.73B | -$2.54B | -$1.27B | $225.00M | -$401.00M | -$592.00M | -$738.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $611.00M | $597.00M | $278.00M | $465.00M | $563.00M | $544.00M | $314.00M | $464.00M | $356.00M | $360.00M | $154.00M | $527.00M |
| Capital expenditures | $166.00M | $138.00M | $114.00M | $158.00M | $144.00M | $108.00M | $117.00M | $123.00M | $106.00M | $92.00M | $104.00M | $72.00M |
| Free cash flow | $445.00M | $459.00M | $164.00M | $307.00M | $419.00M | $436.00M | $197.00M | $341.00M | $250.00M | $268.00M | $50.00M | $455.00M |
Frequently Asked Questions About DGX
What is Quest Diagnostics' annual revenue?
Quest Diagnostics reported revenue of $11.04B for the fiscal year ended Dec 31, 2025.
How fast is Quest Diagnostics' revenue growing?
Revenue was up 11.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.7%.
Is Quest Diagnostics profitable?
Yes. Quest Diagnostics reported net income of $1.05B for the fiscal year ended Dec 31, 2025, with a net margin of 9.5%.
How much free cash flow does DGX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.89B minus capital expenditures of $527.00M produced free cash flow of $1.36B.
How much debt does Quest Diagnostics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $5.17B, short-term debt of $504.00M and cash and equivalents of $420.00M.
DGX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts